Table 1.

Clinical and Molecular Characteristics

Characteristic	PCV/RT (n = 148)		RT (n = 143)
	No.	%	No.	%
Age, years
Median	43		43
Range	18-75		19-76
Age, years*
< 50	102	69	99	69
≥ 50	46	31	44	31
Sex
Male	90	61	84	59
Female	58	39	59	41
Neurologic function
No symptoms	47	32	47	33
Minor symptoms	73	49	69	48
Moderate (active)	17	12	12	8
Moderate (inactive)	11	7	14	10
Unknown	0	0	1	1
KPS*
60-70	15	10	15	10
80-100	133	90	128	90
Surgery
Total resection	40	27	53	37
Partial procedure	85	57	75	52
Biopsy only	21	14	14	10
No details	2	1	1	1
Tumor type
AO	77	52	73	51
AOA (oligodendroglioma dominant)	28	19	37	26
AOA (neither element dominant)	24	16	15	11
AOA (astrocytoma dominant)	19	13	18	13
Tumor grade*
Moderately anaplastic	80	54	81	57
Highly anaplastic	68	46	62	43
Multifocal tumor
Yes	15	10	10	7
No	132	89	131	92
Unknown	1	1	2	1
Corticosteroids at baseline
Yes	92	62	79	55
No	56	38	64	45
Chromosome 1p†
Known	134		128
1p deleted	66	49	76	59
1p intact	68	51	52	41
Unknown	14		15
Chromosome 19q†
Known	135		129
19q deleted	85	63	82	64
19q intact	50	37	47	36
Unknown	13		14
Chromosomes 1p & 19q†
Known	135		128
Both deleted	59	44	67	52
One or neither deleted	76	56	61	48
Unknown	13		15

Abbreviations: AO, anaplastic oligodendroglioma; AOA, anaplastic oligoastrocytoma; KPS, Karnofsky performance status; PCV, procarbazine, lomustine, and vincristine; RT, radiotherapy.

^*Stratification factors at randomization.

^†No. and % of known.